Immune checkpoint inhibitors (ICIs), such as Nivolumab and Pembrolizumab, directed against PD-1, Atezolizumab and Durvalumab directed against PD-L1 and Ipilimumab targeting CTLA-4 and PD-1 display strong efficacy in NSCLC [133]. This evidence concerns the gene CTLA4 and non-small cell lung carcinoma.